All In Biotech

Drug Trial Radar · NCT01373151

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.

Last checked: Nov 20, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

418

Actual

Start

Jun 2011

Primary completion

Sep 2012

Study completion Jun 2015

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jun 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • BMS-945429 PlaceboDrug

    Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only

  • BMS-945429Biological

    Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only

  • BMS-945429Biological

    Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks

  • BMS-945429Biological

    Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48

  • BMS-945429Biological

    Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks

  • MethotrexateDrug

    Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only

  • MethotrexateDrug

    Tablets, Oral, 15 mg, Weekly, 48 weeks

  • Methotrexate PlaceboDrug

    Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only

  • MethotrexateDrug

    Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only

  • Adalimumab PlaceboDrug

    Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks

  • AdalimumabDrug

    Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response RateTime frame: At 12 Weeks

Locations

100 sites in 19 countries. Site status is shown where the registry gives one.

  • Sun Valley Arthritis Center, Ltd.

    Peoria, Arizona

  • San Diego Arthritis Medical Clinic

    San Diego, California

  • New England Research Associates, Llc

    Trumbull, Connecticut

  • Quincy Medical Group

    Quincy, Illinois

  • Rockford Orthopedic Associates, Llc.

    Rockford, Illinois

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • Arthritis Associates Of Mississippi

    Jackson, Mississippi

  • Physician Research Collaboration, Llc

    Lincoln, Nebraska

  • Box Arthritis And Rheumatology Of The Carolinas, Pllc

    Charlotte, North Carolina

  • Health Research Of Oklahoma

    Oklahoma City, Oklahoma

  • East Penn Rheumatology Associates, P.C.

    Bethlehem, Pennsylvania

  • Altoona Center For Clinical Research

    Duncansville, Pennsylvania

  • Seattle Rheumatology Associates

    Seattle, Washington

  • Local Institution

    Córdoba, Argentina

  • Local Institution

    San Juan, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Rosario, Santa Fe Province, Argentina

  • Local Institution

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Local Institution

    Brussels, Belgium

  • Local Institution

    Hasselt, Belgium

  • Local Institution

    São Paulo, Brazil

  • Local Institution

    São Paulo, Brazil

  • Local Institution

    Goiânia, Goiás, Brazil

  • Local Institution

    Juiz de Fora, Minas Gerais, Brazil

  • Local Institution

    Curitiba, Paraná, Brazil

  • Local Institution

    Curitiba, Paraná, Brazil

  • Local Institution

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    Montreal, Quebec, Canada

  • Local Institution

    Québec, Quebec, Canada

  • Centre De Recherche Musculo-Squelettique

    Trois-Rivières, Quebec, Canada

  • Local Institution

    Prague, Czechia

  • Local Institution

    Prague, Czechia

  • Local Institution

    Bordeaux, France

  • Local Institution

    Chambray-lès-Tours, France

  • Local Institution

    Strasbourg, France

  • Local Institution

    Berlin, Germany

  • Local Institution

    Cologne, Germany

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.